ANNX vs IMVT
ANNX: Annexon is a clinical-stage biotechnology company developing C1q-inhibitor therapies to treat neurodegenerative and autoimmune diseases driven by the classical complement pathway. IMVT: Immunovant is a clinical-stage immunology company developing IMVT-1402, a potentially best-in-class FcRn inhibitor to treat autoimmune diseases driven by pathogenic IgG antibodies.
Side-by-side fundamentals
| Metric | ANNX | IMVT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.23 | $39.05 | |
| Market cap as of 2026-07-23 | $857M | $8.0B | |
| PEG as of 2026-07-23 | -1.19 | -11.69 | IMVT lower |
| ROE as of 2026-07-23 | -101.2% | -68.2% | IMVT higher |
| ROA as of 2026-07-23 | -76.0% | -62.2% | IMVT higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 1.18 | 0.81 | |
| 1-year return as of 2026-07-22 close | +118.2% | +123.3% | IMVT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.